Associations between <i>Shigella</i> infections and EE biomarker concentrations from time of index subclinical <i>Shigella</i> detection through 6-months post-detection, stratified... by Haley A. Liakakos (21445884)

Subjects:

Characteristics of non-diarrheal stool samples from 1715 children in MAL-ED study. by Haley A. Liakakos (21445884)

Subjects:

Johnsen testicular biopsy score. by Halime Tozak Yıldız (21238185)

Subjects:

Nanoparticle tracking analysis. by Halime Tozak Yıldız (21238185)

Subjects:

Sperm count and motility. by Halime Tozak Yıldız (21238185)

Subjects:

The influence of H₂O₂ on <i>P</i>. <i>berghei</i> infection in <i>A</i>. <i>stephensi</i>. by Li Gao (131516)

Subjects:

PA inhibits PI3K/AKT pathways in osteosarcoma cells. by Zeyu Zhan (22305085)

Subjects:

The global changes of prevalence (A-C), DALYs (D-F), and mortality (G-I) rates of IBD among WCBA from 1990 to 2021. by Jiefeng Zhao (9090305)

Subjects:

Structural alterations in hydrogen bond networks of the TP53 protein caused by mutations G266E (A-B), G105C (C-D), R273C (E-F), R280G (G-H), and Q136P (I-J). by Ashraf Attia Mahmoud (21262201)

Subjects:

Fig 6 - by Samuel Hylander (331771)

Fig 1 - by Samuel Hylander (331771)

Discovery of an Orally Active PDE1 Inhibitor for Disease-Modifying Treatment of Postmenopausal Osteoporosis via Dual Anabolic-Antiresorptive Mechanisms by Farman M. Abbasi (22318766)

“…In ovariectomized mice, <b>5cc</b> administration (5 mg/kg) improved the trabecular microarchitecture, bone mineral density, and strength, at levels comparable to teriparatide, while significantly reducing bone resorption markers. With 13.57% oral bioavailability and selectivity for PDE1A1 (32% inhibition at 500 nM), <b>5cc</b> offers an innovative therapeutic candidate for PMO with a dual anabolic-antiresorptive profile and oral efficacy, warranting further clinical development.…”

Discovery of an Orally Active PDE1 Inhibitor for Disease-Modifying Treatment of Postmenopausal Osteoporosis via Dual Anabolic-Antiresorptive Mechanisms by Farman M. Abbasi (22318766)

“…In ovariectomized mice, <b>5cc</b> administration (5 mg/kg) improved the trabecular microarchitecture, bone mineral density, and strength, at levels comparable to teriparatide, while significantly reducing bone resorption markers. With 13.57% oral bioavailability and selectivity for PDE1A1 (32% inhibition at 500 nM), <b>5cc</b> offers an innovative therapeutic candidate for PMO with a dual anabolic-antiresorptive profile and oral efficacy, warranting further clinical development.…”

Discovery of an Orally Active PDE1 Inhibitor for Disease-Modifying Treatment of Postmenopausal Osteoporosis via Dual Anabolic-Antiresorptive Mechanisms by Farman M. Abbasi (22318766)

“…In ovariectomized mice, <b>5cc</b> administration (5 mg/kg) improved the trabecular microarchitecture, bone mineral density, and strength, at levels comparable to teriparatide, while significantly reducing bone resorption markers. With 13.57% oral bioavailability and selectivity for PDE1A1 (32% inhibition at 500 nM), <b>5cc</b> offers an innovative therapeutic candidate for PMO with a dual anabolic-antiresorptive profile and oral efficacy, warranting further clinical development.…”

Flow chart of data screening and analysis. by Yan She (8639796)

Subjects:

Fig 4 - by Samuel Hylander (331771)

Fig 3 - by Samuel Hylander (331771)

Lifespan of a single <i>T. utriculata</i> rosette. by Alexandra M. Campbell (3284094)

Subjects:

Proportion of L3 recovered from forages. by Katy A. Martin (9216905)

The mean number of the emerged <i>D. melanogaster</i> adults. Mean number (±SE) of emerged adults and average percentage (±SE) of the residual fertility at the different treatment... by Flavia Cerasti (21655934)

Subjects: